Appointment dossier — Endometrioid Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrioid Carcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT04111978 · Phase 3 — MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (Austria)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
- NCT05945407 — Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer (China)
- NCT06466382 — OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy (Switzerland)
- NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT06690775 · Phase 2 — CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (United States)
- NCT05920798 · Phase 1 / Phase 2 — Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (United States)
- NCT05997017 · Phase 2 — Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer (United States)
- NCT06639074 · Phase 2 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (United States)
- NCT05112601 · Phase 2 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (United States)
- NCT04919629 · Phase 2 — APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (United States)
- NCT06463028 · Phase 2 — Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer (United States)
- NCT05231122 · Phase 2 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (United States)
- NCT05403554 · Phase 1 — A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers (France)
Most-relevant first: trials that name Endometrioid Carcinoma, then broader trials you may still qualify for. 25 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT04111978), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?